SecBot SecBot
8-K ·Filed Feb 26, 2026

EWTX

Edgewise Therapeutics, Inc.
NEUTRAL
Impact 4/10
Horizonmonths Processed8mo ago SEC0001104659-26-020108
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

Monitor upcoming clinical data readouts in H1 2026 for EDG-7500 and EDG-15400, and the pivotal GRAND CANYON data in Q4 2026, which could be key value drivers for the stock.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$29.66
T+0 close · Feb 26, 2026 · via day close
Latest settled
+10.22%
T+60 · $32.69
Vs SPY
+2.47%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Feb 26 $29.66entry
  2. T+1 · 9mo ago +2.63%α +3.08% · $30.44
  3. T+5 · 9mo ago −4.28%α −3.15% · $28.39
  4. T+20 · 8mo ago +6.71%α +13.11% · $31.65
  5. T+60 · 6mo ago +10.22%α +2.47% · $32.69
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Edgewise Therapeutics reported Q4 2025 financial results with a net loss of $50.2 million and $530.1 million in cash. The company highlighted near-term catalysts including upcoming data readouts for EDG-7500 in HCM (H1 2026), EDG-15400 in heart failure (H1 2026), and pivotal GRAND CANYON data for sevasemten in Becker muscular dystrophy (Q4 2026).

Key Financial Metrics

EPS
$-0.47

Key Facts

  • Cash, cash equivalents and marketable securities: $530.1 million as of December 31, 2025
  • R&D expenses: $43.6 million for Q4 2025 (up from $37.5 million in Q3)
  • G&A expenses: $12.4 million for Q4 2025 (up from $9.4 million in Q3)
  • Net loss: $50.2 million or $0.47 per share for Q4 2025
  • Upcoming catalysts: CIRRUS-HCM 12-week data (H1 2026), EDG-15400 Phase 1 data (H1 2026), GRAND CANYON pivotal data (Q4 2026)

Financial Impact

Net loss increased to $50.2 million in Q4 2025 from $40.7 million in Q3 2025, with R&D and G&A expenses both increasing significantly

net lossr&d expensesg&a expenses

Risk Factors

  • Clinical trial results may not meet expectations
  • Regulatory approval risks for sevasemten
  • Need for substantial additional capital to finance operations

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-020108
Document: tm266859d1_8k.htm0001104659-26-020108
Document: 0001104659-26-020108-index-headers.html0001104659-26-020108
Document: 0001104659-26-020108-index.html0001104659-26-020108
Document: 0001104659-26-020108.txt0001104659-26-020108

US Market Status

Market Closed · Opens in 8h 7m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Feb 26, 2026